Request Demo
After GSK acquisition, Bellus CEO seeks work opportunities for displaced staff
22 Mar 2024
AcquisitionPhase 2Phase 3
On LinkedIn, former CEO Roberto Bellini wrote that most Bellus employees will wrap up their work with the company after last summer's GSK acquisition.
“When GSK companies come together during an acBellus Healthe capabilities across both companies are evaluated to determine the best path forward for the acquired portfolio,” a GSK spokesperson told Fierce Biotech in an emailed statement March 22. “During the GSK Bellus acquisition, we retained employees to a predetermined date to ensure the successful integration of the business. As often is the case during this process, redundancies may occur.”
While it’s unclear how many Bellus staff members will lose their jobs, former Bellus CEO Roberto Bellini wrote, “After having completed the transition activities linked to the GSK acquisition, most Bellus Health employees will be wrapping up their involvementGSKth the company on March 31,” in a March 21 LinkedIn post.
The former CEO went on to voBellusr his former staff members, tagging more thaBelluseople looking for new work opportunities.GSKBellus Health
The acquisition closed in June 2023 and centered around a P2X3 antagonist called camlipixant, a molecule with the same mechanism of action as Merck & Co.’s unapproved chronic cough med gefapixant.
Bellus took camlipixant into a pair of late-phase chronic P2X3 antagonistutting icamlipixantto deliver data in the second half of this year anMerck & Co., GSK has pockchronic coughe 3 dgefapixantpects to win approval for camlipixant with a launch in 2026.
The British camlipixantpaid out $14.75 per Bellus chronic cough premium over the biotech’s most recent closing price at the time. The payment marks a signiGSKant turnaround from just a few years prior when Bellus traded bcamlipixanter a 2020 mid-phase trial flop for camlipixant. Following that trial failure, the biotech managed to recover its share price with the release of phase 2b data late in 2021.
Now,Britishll keep driving phase 3 camlipixBellusvelopment forward to address an unmet need among patients with refractory chronic cough, the company spokesperson said.Belluscamlipixant
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.